secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001213900-24-107906
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics raises $100M in public offering to fund TARA-002 clinical development
--------------------------------------------------------------------------------

- Gross proceeds of ~$100M from offering of 13.69M shares and 2.33M pre-funded warrants at $6.25/share.
- Proceeds to fund clinical development of TARA-002 for cancer and rare diseases; also working capital.
- Underwriters granted 30-day option to purchase up to 2.4M additional shares; company and insiders have 60-day lock-up.
- Offering closed December 11, 2024; TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., Scotiabank acted as joint book-runners.
- Pre-funded warrants exercisable at $0.001, with ownership limitation of 4.99% (adjustable to 19.99%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024107906/0001213900-24-107906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024107906/ea0224389-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-107906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer